New approach to treat eye cancer
A research team from Germany and Mexico has successfully targeted uveal melanoma (UM), the most common type of eye cancer.
Pfizer buys stake in liver gene therapy player Vivet
Pfizer Inc has paid 45m upfront to French gene therapy specalist Vivet Therapeutics in a licence option deal for Vivet’s preclinical Wilson disease candidate VTX-801.
Sotio on track for 2nd Phase III trial
After positive preliminary results of Sotio’s SOV02 trial in ovarian cancer had been presented last year, the final analysis confirmed the survival benefits. The Czech biotech company now plans to initiate a global Phase III study with its autologous cell-based immunotherapy also in this indication.
AMR Conference in Berlin: Call for better incentives
More than 330 experts joined the 2-day AMR Conference 2019 in Berlin. They called for rapid capital investments and economic incentives in the fight against antimicrobial resistance (AMR).
Biomarker can exclude acute kidney injury
Researchers target neuroblastoma with ALK-ADC
Researchers at Celldex Therapeutics, Inc and Nerviano Medical Science Srl report elimination of the most common childhood cancer by an ADC in xenografted mice expressing either wild-type or mutated ALK.
AMR: Germany set to invest 39m into CARB-X
Global antibacterial innovation network CARB-X announced during an AMR business conference in Berlin that Germany has joined the CARB-X partnership.
AstraZeneca partners with Seres Therapeutics
Under a three-year agreement, British pharma giant AstraZeneca plc pays 20m and R&D costs to Seres Therapeutics Inc, which will identify patterns in the microbiome predicting therapy response to cancer immune therapies.
Small-molecule acts as broad-band influenza entry blocker
Researchers at Janssen Pharmaceutical Companies of Johnson & Johnson in Leiden have developed a small molecule antibody mimic, that prevents entry of multiple influenza virus serotypes.
Seventure starts second microbiome-focussed fund
Seventure Partners has announced the first close of its second microbiome fund designed to put 200m in 20 companies developing microbiome-based health solutions.